Lipocine announces first patient dosed in Phase 2a study of LPCN 1111 Lipocine announced that the first patient has been dosed in a Phase 2a clinical study of LPCN 1111, a novel ester prodrug of testosterone, in hypogonadal males. The primary objectives of the study will be to determine safety, tolerability, single and steady state pharmacokinetics of testosterone following oral administration of LPCN 1111.
Lipocine reports 'acceptable' LPCN 1021 results In a regulatory filing earlier, Lipocine provided data on its phase 3 SOAR study of LPCN 1021, an oral testosterone product. The company first presented the data at the American Urological Association meeting on May 18. According to the presentation, LPCN 1021 produced "acceptable" results which were "generally consistent" with U.S. FDA target guidelines. The company notes that LPCN 1021 "may" improve patient compliance.